CC
HRMY icon

Centiva Capital’s Harmony Biosciences HRMY Stock Holding History

Centiva Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,484
Closed -$381K – 1774
2025
Q1 		$381K Sell
11,484
-5,189
-31% -$186K 0.01% 964
2024
Q4 		$574K Sell
16,673
-5,817
-26% -$200K 0.01% 739
2024
Q3 		$900K Sell
22,490
-7,458
-25% -$262K 0.02% 912
2024
Q2 		$904K Buy
29,948
+19,625
+190% +$590K 0.02% 834
2024
Q1 		$347K Sell
10,323
-11,237
-52% -$361K 0.01% 1173
2023
Q4 		$696K Buy
+21,560
New +$602K 0.02% 797

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's HRMY Position: Q2 2025 in Review

Centiva Capital sold out of Harmony Biosciences (HRMY) in Q2 2025, closing a stake of 11,484 shares — an estimated $381K sold.

Centiva Capital first reported a position in HRMY in Q4 2023 and held it in 6 quarters. The position peaked at $904K in Q2 2024. 279 funds tracked by Wall St. Rank hold HRMY as of Q2 2025.

  • Centiva Capital reported no remaining Harmony Biosciences position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 11,484 Harmony Biosciences shares in Q2 2025, an estimated $381K.
  • Centiva Capital first reported a position in Harmony Biosciences in Q4 2023 and held it in 6 quarters.
  • Centiva Capital's Harmony Biosciences position peaked at $904K in Q2 2024.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.